- Home
- LSF vs IMRX Comparison
LSF vs IMRX Comparison
Compare LSF & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | IMRX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 232.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSF | IMRX |
|---|---|---|
| Price | $2.11 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $17.20 |
| AVG Volume (30 Days) | 88.6K | ★ 819.3K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.08 | $1.10 |
| 52 Week High | $8.96 | $10.08 |
Technical Indicators
Market Signals| Indicator | LSF | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 40.95 |
| Support Level | $2.13 | $5.93 |
| Resistance Level | $2.52 | $6.54 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 0.65 | 15.30 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.